My research focuses on research in epidemiology and outcomes of inflammatory bowel diseases and development of personalized medicine approach.
Research & Clinical Trials
Researching mucosal immunology and inflammatory bowel disease.
The CSIBD Clinical Core provides an infrastructure to facilitate the translation of basic research findings into a clinical setting.
The Corcoran laboratory focuses on developing new and effective therapies for gastrointestinal cancers, such as colorectal and pancreatic cancers, by targeting the specific survival signals that are active in a given patient's cancer.
Our laboratory seeks to gain new insights into the molecular pathogenesis of tumors of the GI tract. Our particular areas of interest are colon cancer, neuroendocrine tumors, angiogenesis, hypoxia, hereditary cancers, and genetic instability. We seek to identify molecular targets that can ultimately guide therapeutic strategies.
We study transcriptional regulation of gastrointestinal and hepatobiliary development and its application to regenerative medicine and cancer.
Our core develops genetic technologies and model systems aimed at investigating genes and pathways to yield insight into how human genomic variants affect the pathogenesis of IBD.
The lab is interested in two major topics: 1) The role of post-transcriptional RNA chemical modifications (“epitranscriptomics”) on biological functions 2) The role of RNA-binding protein (RBP) interactomes in epigenetic and post-transcriptional regulatory systems implicated in human autoimmune diseases
Our laboratory has been involved in uncovering the mechanisms by which hepatitis viruses, particularly hepatitis C, persist in the liver and cause liver damage.
Dr. Dienstag is an experienced clinical investigator in the area of viral hepatitis (trials of antiviral therapies for chronic hepatitis B and C). Between 2000 and 2010, he was the site-PI of a national trial of maintenance antiviral therapy for patients refractory to treatment for chronic hepatitis C, the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial.
The Patient Gateway provides secure online access to your health information whenever you need it. Check upcoming appointments, communicate with your doctor’s office, review medications and pay medical bills—all seamlessly online 24/7.